Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Mais filtros

Base de dados
Intervalo de ano de publicação
Cancer Cell Int ; 18: 108, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30087582


Background: The prognostic significance of galectin-1 (Gal-1) expression in cancerous patients has been assessed for several years while the results remain controversial. Thus, we performed the first comprehensive meta-analysis to evaluate the prognostic value of Gal-1 expression in cancerous patients. Methods: We searched Pubmed, Embase and Web of Science to recruit studies on the prognostic impact of Gal-1 expression in cancerous patients. Eighteen studies containing 2674 patients were involved in this meta-analysis until March 30, 2018. Pooled hazard ratios (HRs) with 95% confidence interval (95% CI) were calculated to estimate the effect using random-effects model. Results: The pooled results revealed that high Gal-1 expression in cancer tissue associated with a poor OS (HR = 1.79, 95% CI 1.54-2.08, P < 0.001). In the subgroup of tumor type, it's observed that high Gal-1 expression was significant correlated with poor OS in digestive cancers without heterogeneity (HR = 1.94, 95% CI 1.64-2.30, P < 0.001; fixed-effects model; I2 = 20.1%, P = 0.276). Conclusions: Our present meta-analysis indicates that high Gal-1 expression might be a predictive factor of poor prognosis in cancers, particularly in digestive cancers.

Cell Physiol Biochem ; 45(3): 993-1002, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29428936


BACKGROUND/AIMS: Recently, many studies have demonstrated that galectin-9 (Gal-9) exhibits altered expression and has a close association with metastasis and recurrence in various cancers. Therefore, we conducted a meta-analysis to assess the prognostic role of Gal-9 expression in solid tumours. METHODS: We searched PubMed, Embase, and Web of Science until June 2017 and identified fourteen eligible studies containing 2,408 patients to include in the meta-analysis. RESULTS: The pooled results indicated that higher Gal-9 expression in cancer tissue associated with an improved CSS (HR=0.48, 95% CI 0.39-0.58). In the subgroup analysis, a significant relationship was observed between higher Gal-9 expression and both CSS (HR=0.48, 95% CI 0.39-0.59) and OS (HR=0.62, 95% CI 0.49-0.78) in digestive cancers. CONCLUSIONS: The findings of this meta-analysis highlight the role of Gal-9 as a useful clinical prognostic biomarker, which may facilitate the treatment of patients with solid tumours.

Biomarcadores Tumorais/metabolismo , Galectinas/metabolismo , Neoplasias/diagnóstico , Biomarcadores Tumorais/genética , Bases de Dados Factuais , Intervalo Livre de Doença , Galectinas/genética , Humanos , Neoplasias/metabolismo , Neoplasias/mortalidade , Razão de Chances , Prognóstico , Modelos de Riscos Proporcionais , Taxa de Sobrevida
Onco Targets Ther ; 9: 6701-6710, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27822073


Recently, many studies have shown that pretreatment serum albumin can be closely linked to the prognosis of cancer patients, including those with renal cell carcinoma (RCC). However, not all studies have reached the same conclusion. We therefore conducted a systematic review and meta-analysis to evaluate the prognostic value of pretreatment serum albumin in RCC patients. A total of 17 studies involving 6,447 patients were included in our meta-analysis. Our results indicated that a lower pretreatment serum albumin level yielded a worse overall survival (hazard ratio [HR]=2.46, 95% confidence interval [CI] 1.92-3.13), cancer-specific survival (HR=2.22, 95% CI 1.87-2.64), and relapse-free survival/progression-free survival (HR=1.75, 95% CI 1.28-2.38). Generally, these findings were particularly pronounced when stratified by tumor type, analysis type, cut-off value, and HR-obtaining method. In conclusion, a decreased pretreatment serum albumin level implies a poor prognosis for RCC patients, and can be monitored for risk stratification and individualized treatment in RCC patients.